Evaluation of the effect of arsenic trioxide adding to standard regimen 7-3 in acute myeloid leukemia patients: a Randomized single blind clinical trial

Hematology, Oncology & Stem Cell Transplantation Research Center, Tehran University of Medical Sci.0 个研究点目标入组 112 人开始时间: 待定最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients with a newly diagnosis of AML according to the criteria of the WHO 2016 revision
•Age 15-59years
•Diagnosis of primary AML other than acute promyeloctic leukemia (AML M3),
•Adequate liver (serum bilirubin level < 2upper normal limit) and renal function test (serum creatinine <1.5upper normal limit or creatinine clearance >60)
•Normal cardiac function
•Females of childbearing age must have a negative serum pregnancy test
•Signed consent

•Newly diagnosed patients older than age 60.
•CML in blastic crisis
•Patients with cardiopathies including recurrent supraventricular arrhythmia and any type of sustained ventricular arrhythmia or conduction block (A-V block grade II or III)
•Pregnant or breastfeeding women
•History of preexisting neurological disorders ( seizure disorders)
•Patients with active second malignancy, excluding adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix

发起方

Hematology, Oncology & Stem Cell Transplantation Research Center, Tehran University of Medical Sci.